Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598169 · ClinicalTrials.gov registry record · Phase 1
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00598169 is a Phase 1 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 23 participants.
The verdict
NCT00598169, a Phase 1 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether giving bortezomib together with combination chemotherapy is more effective with or without rituximab in treating AIDS-related non-Hodgkin lymphoma. PURPOSE: This clinical trial is studying giving bortezomib together with dexamethasone, ifosfamide, carboplatin, and etoposide to see how well it works with or without rituximab in treating patients with relapsed or refractory AIDS-related non-Hodgkin lymphoma.
Interventions
- DRUG carboplatin
- BIOLOGICAL rituximab
- DRUG dexamethasone
- DRUG etoposide
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598169
The ClinicalTrials.gov registry entry for NCT00598169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00598169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598169 about?
NCT00598169 is a clinical study titled "Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma". RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer ce...
What is the current status of trial NCT00598169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00598169?
The interventions under investigation include: carboplatin (DRUG), rituximab (BIOLOGICAL), dexamethasone (DRUG), etoposide (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00598169?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.